Dr. Esteves is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3809 spring street
Racine, WI 53405Phone+1 262-687-5000Fax+1 262-687-5098
Education & Training
Oklahoma State University Center for Health SciencesClass of 2011
Certifications & Licensure
IL State License 2024 - 2026
AZ State License 2024 - 2025
CO State License 2020 - 2025
MT State License 2024 - 2025
ND State License 2021 - 2025
OK State License 2012 - 2025
TX State License 2024 - 2025- AOA Board of Internal Medicine Internal Medicine
- AOA Board of Internal Medicine Oncology
- Join now to see all
Publications & Presentations
PubMed
- 311 citationsTivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III TrialRobert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy
Journal of Clinical Oncology. 2013-10-20 - 78 citationsBiologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedu...Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhargava, Toshiyuki Isoe, Monette M. Cotreau
Clinical Cancer Research. 2011-11-15 - 86 citationsAntitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell CarcinomaDmitry Nosov, Brooke Esteves, Oleg Lipatov, Alexei A. Lyulko, A. A. Anischenko
Journal of Clinical Oncology. 2012-05-10
Press Mentions
Who's News: Nov. 6November 5th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
